What type of study is this?

This is a Case Report study (also classified as: Meta-Analysis, Systematic Review).

December 8, 2025Blood

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

MGMaria Gavriilaki PEPaschalis Evangelidis NENikolaos Evangelidis

Discussion

Member takes

Implication

Systematic review and meta-analysis reveals tocilizumab prophylaxis reduced cytokine release syndrome incidence in patients with hematological malignancies receiving CAR-T immunotherapy.

Key Points

Prophylactic tocilizumab significantly reduced any grade cytokine release syndrome risk in CAR-T patients.
Among 91 patients analyzed, those receiving tocilizumab had a 56% lower risk of cytokine release syndrome.
Systematic review and meta-analysis conducted on hematological malignancies with diverse CAR-T products.
Findings suggest potential benefits of tocilizumab prophylaxis, indicating need for larger randomized trials.

Cite This Study

Gavriilaki et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e26b https://doi.org/10.1182/blood-2025-7668

View Full Paper

Ask AI

Bookmark

Implication

Systematic review and meta-analysis reveals tocilizumab prophylaxis reduced cytokine release syndrome incidence in patients with hematological malignancies receiving CAR-T immunotherapy.

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider